Guidelines for HER2 testing in the UK.
作者信息
Hsi E D, Tubbs R R
出版信息
J Clin Pathol. 2004 Mar;57(3):241-2. doi: 10.1136/jcp.2003.009308.
Abstract
摘要
相似文献
1
Guidelines for HER2 testing in the UK.
J Clin Pathol. 2004 Mar;57(3):241-2. doi: 10.1136/jcp.2003.009308.
2
Best Practice No 176: Updated recommendations for HER2 testing in the UK.
J Clin Pathol. 2004 Mar;57(3):233-7. doi: 10.1136/jcp.2003.007724.
3
Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Arch Pathol Lab Med. 2016 Feb;140(2):140-7. doi: 10.5858/arpa.2015-0108-OA.
4
HER2 Immunohistochemistry-Guided Targeted Fluorescence In Situ Hybridization Analysis Does Not Help Identify Intratumoral Heterogeneity in Breast Cancer.
Arch Pathol Lab Med. 2016 Aug;140(8):741. doi: 10.5858/arpa.2016-0015-LE.
5
Human epidermal growth factor receptor 2 testing in breast cancer.
J Clin Oncol. 2007 Sep 1;25(25):4020; author reply 4021-3. doi: 10.1200/JCO.2007.10.8522.
6
What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard.
Am J Clin Pathol. 2008 Dec;130(6):883-91. doi: 10.1309/AJCP5UUMFMA5ZKII.
7
[Assessment of HER2 status in breast cancer].
Bull Cancer. 2004 Dec 1;91 Suppl 4:S211-5.
8
[Guidelines for HER2 detection in breast cancer, the 2014 version].
Zhonghua Bing Li Xue Za Zhi. 2014 Apr;43(4):262-7.
9
Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.
Am J Clin Pathol. 2010 Aug;134(2):284-92. doi: 10.1309/AJCPUQB18XZOHHBJ.
10
Saving lives with accurate HER2 testing.
Am J Clin Pathol. 2010 Aug;134(2):183-4. doi: 10.1309/AJCP6VZ8YHMZNNED.
引用本文的文献
1
Observer performance in the use of digital and optical microscopy for the interpretation of tissue-based biomarkers.
Anal Cell Pathol (Amst). 2014;2014:157308. doi: 10.1155/2014/157308. Epub 2014 Nov 11.
2
External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale.
J Exp Clin Cancer Res. 2013 Aug 21;32(1):58. doi: 10.1186/1756-9966-32-58.
3
p16 expression correlates with basal-like triple-negative breast carcinoma.
Ecancermedicalscience. 2013 May 14;7:317. doi: 10.3332/ecancer.2013.317. Print 2013.
4
Multiparameter DNA content analysis identifies distinct groups in primary breast cancer.
Br J Cancer. 2013 Mar 5;108(4):873-80. doi: 10.1038/bjc.2013.42. Epub 2013 Feb 14.
5
Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.
Patholog Res Int. 2010 Jun 28;2010:814176. doi: 10.4061/2010/814176.
6
Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation.
Histopathology. 2010 Jul;57(1):27-38. doi: 10.1111/j.1365-2559.2010.03577.x. Epub 2010 Jun 24.
7
Virtual microscopy as an enabler of automated/quantitative assessment of protein expression in TMAs.
Histochem Cell Biol. 2008 Sep;130(3):447-63. doi: 10.1007/s00418-008-0480-1. Epub 2008 Aug 5.
8
Serum HER-2 concentration in patients with primary breast cancer.
J Clin Pathol. 2006 Apr;59(4):373-6. doi: 10.1136/jcp.2005.029603. Epub 2006 Feb 3.
9
Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma.
J Clin Pathol. 2005 May;58(5):500-3. doi: 10.1136/jcp.2004.023556.
本文引用的文献
1
Best Practice No 176: Updated recommendations for HER2 testing in the UK.
J Clin Pathol. 2004 Mar;57(3):233-7. doi: 10.1136/jcp.2003.007724.
2
Anticancer antibodies.
Am J Clin Pathol. 2003 Apr;119(4):472-85. doi: 10.1309/Y6LP-C0LR-726L-9DX9.
3
Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries.
Am J Clin Pathol. 2002 Sep;118(3):408-17. doi: 10.1309/97WN-W6UX-XJWT-02H2.
4
Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing.
Arch Pathol Lab Med. 2002 Jul;126(7):803-8. doi: 10.5858/2002-126-0803-CLAFHN.
5
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.
J Natl Cancer Inst. 2002 Jun 5;94(11):855-7. doi: 10.1093/jnci/94.11.855.
6
Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification.
Am J Pathol. 2002 May;160(5):1589-95. doi: 10.1016/S0002-9440(10)61106-6.
7
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
Am J Pathol. 2000 Nov;157(5):1467-72. doi: 10.1016/S0002-9440(10)64785-2.
8
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
J Clin Oncol. 2000 Nov 1;18(21):3651-64. doi: 10.1200/JCO.2000.18.21.3651.
9
Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.
Cancer Res. 1994 May 15;54(10):2771-7.
Zotero 插件